Dyne Therapeutics (DYN)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Dyne Therapeutics (DYN)
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
Key Insights
Critical company metrics and information
Share Price
$28.82Market Cap
$2.93 BillionTotal Outstanding Shares
101.77 Million SharesTotal Employees
173Dividend
No dividendIPO Date
September 17, 2020SIC Description
Pharmaceutical PreparationsHomepage
https://www.dyne-tx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $806.41 Million |
Net Cash Flow From Operating Activities, Continuing | $-243.04 Million |
Net Cash Flow From Operating Activities | $-243.04 Million |
Net Cash Flow | $401.50 Million |
Net Cash Flow, Continuing | $401.50 Million |
Net Cash Flow From Investing Activities | $-161.87 Million |
Net Cash Flow From Investing Activities, Continuing | $-161.87 Million |
Net Cash Flow From Financing Activities, Continuing | $806.41 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Operating Income/Loss | $-314.47 Million |
Revenues | $0.00 |
Net Income/Loss Available To Common Stockholders, Basic | $-294.51 Million |
Basic Earnings Per Share | $3.56 |
Income/Loss From Continuing Operations Before Tax | $-294.51 Million |
Operating Expenses | $314.47 Million |
Research and Development | $258.45 Million |
Income/Loss From Continuing Operations After Tax | $-294.51 Million |
Net Income/Loss Attributable To Parent | $-294.51 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Other Operating Expenses | $56.02 Million |
Diluted Earnings Per Share | $3.56 |
Net Income/Loss | $-294.51 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Assets | $736.39 Million |
Other Current Liabilities | $25.79 Million |
Assets | $768.84 Million |
Wages | $11.31 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Accounts Payable | $6.16 Million |
Equity | $705.54 Million |
Liabilities | $63.30 Million |
Liabilities And Equity | $768.84 Million |
Fixed Assets | $4.90 Million |
Noncurrent Assets | $32.45 Million |
Other Non-current Assets | $27.56 Million |
Equity Attributable To Parent | $705.54 Million |
Noncurrent Liabilities | $20.04 Million |
Current Liabilities | $43.26 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.